Investments
82Portfolio Exits
12Funds
5About BioStar Capital
BioStar Capital is a value-add investor focused on transformational medical device technologies in cardiovascular and orthopaedic medicine. Combining the insight of experienced investment professionals and medical thought leaders, BioStar Capital identifies proprietary technologies that serve unmet patient needs and fit the acquisition criteria of leading medical device companies. BioStar Capital fills an important gap in medical device development and provides operational skills and clinical expertise in addition to capital, enabling the firm to actively mitigate risk, optimize product development, and secure successful exit.
BioStar Capital Headquarter Location
560 W. Mitchell Street #480
Petoskey, Michigan, 49770,
United States
231-487-9186
Expert Collections containing BioStar Capital
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find BioStar Capital in 1 Expert Collection, including Pharma Startups.
Pharma Startups
5,090 items
Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.
Latest BioStar Capital News
May 26, 2021
Jeffrey Yau, PhD, VP of Data Science and Engineering at Walmart Global Technology, Joins BioStar Capital as Entrepreneur in Residence 0 PETOSKEY, Mich.–( BUSINESS WIRE )– BioStar Capital , a value-add investment firm focused on transformational medical device technologies that serve unmet patient and physician needs, today announced that Jeffrey Yau, PhD in Economics and VP of Data Science, Data Engineering, and Platform Engineering of Store Associate Tech at Walmart Global Technology, has joined the firm as an entrepreneur in residence (EIR). Dr. Yau was also previously Chief Data Scientist at AllianceBernstein, a global investment management and research firm with almost $700B in assets under management. As an EIR, Dr. Yau will expand BioStar’s expertise within the emerging field of data science and artificial intelligence (AI) in healthcare, as well as…
BioStar Capital Investments
82 Investments
BioStar Capital has made 82 investments. Their latest investment was in Calcium Solutions as part of their Seed VC on July 7, 2020.
BioStar Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
7/7/2020 | Seed VC | Calcium Solutions | $1.24M | Yes | 1 | |
6/22/2020 | Series D | Foldax | $20M | No | Angel Physicians Fund, California Institute of Technology, Kairos Ventures, MemorialCare Innovation Fund, and Sayan Bioventures | 7 |
6/3/2020 | Unattributed VC - IV | NeuroClear Technologies | $10.75M | No | 1 | |
1/21/2020 | Series B | |||||
11/5/2019 | Unattributed VC - III |
Date | 7/7/2020 | 6/22/2020 | 6/3/2020 | 1/21/2020 | 11/5/2019 |
|---|---|---|---|---|---|
Round | Seed VC | Series D | Unattributed VC - IV | Series B | Unattributed VC - III |
Company | Calcium Solutions | Foldax | NeuroClear Technologies | ||
Amount | $1.24M | $20M | $10.75M | ||
New? | Yes | No | No | ||
Co-Investors | Angel Physicians Fund, California Institute of Technology, Kairos Ventures, MemorialCare Innovation Fund, and Sayan Bioventures | ||||
Sources | 1 | 7 | 1 |
BioStar Capital Portfolio Exits
12 Portfolio Exits
BioStar Capital has 12 portfolio exits. Their latest portfolio exit was TransMedics on May 02, 2019.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
5/2/2019 | IPO | 2 | |||
9/21/2018 | IPO | 1 | |||
8/10/2016 | Merger | 1 | |||
Date | 5/2/2019 | 9/21/2018 | 8/10/2016 | ||
|---|---|---|---|---|---|
Exit | IPO | IPO | Merger | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 2 | 1 | 1 |
BioStar Capital Fund History
5 Fund Histories
BioStar Capital has 5 funds, including BioStar Ventures III.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
9/16/2015 | BioStar Ventures III | Early-Stage Venture Capital | $67.72M | 3 | |
9/30/2010 | BioStar Ventures II LP | ||||
2/1/2005 | BioStar Private Equity Fund | ||||
BSV III-XF ASI SPV | |||||
BioStar Ventures III-XF |
Closing Date | 9/16/2015 | 9/30/2010 | 2/1/2005 | ||
|---|---|---|---|---|---|
Fund | BioStar Ventures III | BioStar Ventures II LP | BioStar Private Equity Fund | BSV III-XF ASI SPV | BioStar Ventures III-XF |
Fund Type | Early-Stage Venture Capital | ||||
Status | |||||
Amount | $67.72M | ||||
Sources | 3 |
BioStar Capital Team
8 Team Members
BioStar Capital has 8 team members, including current Chief Financial Officer, Paul A. Scott.
Name | Work History | Title | Status |
|---|---|---|---|
Paul A. Scott | Chief Financial Officer | Current | |
Lisa Riedmiller | Controller | Current | |
Steven L. Almany | Managing Director | Current | |
Renee Masi | Managing Director | Current | |
Jeffrey F. O'Donnell | Managing Director | Current |
Name | Paul A. Scott | Lisa Riedmiller | Steven L. Almany | Renee Masi | Jeffrey F. O'Donnell |
|---|---|---|---|---|---|
Work History | |||||
Title | Chief Financial Officer | Controller | Managing Director | Managing Director | Managing Director |
Status | Current | Current | Current | Current | Current |